



NEWS RELEASE

For Further Information Contact:

Roy Wolvin
Nymox Pharmaceutical Corporation
800-93NYMOX
www.nymox.com

For Immediate Release:

Recent Clinical Trial data for Nymox NX-1207 Drug to Be Presented at American Urological Association Meeting in Monterey on Thursday

Nymox Drug in Phase 3 Program

HASBROUCK HEIGHTS, N.J. (October 28, 2008) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that recent results of clinical studies of NX-1207, the Company's investigational drug for the treatment of benign prostatic hyperplasia (BPH) or enlarged prostate, will be presented this Thursday at the 84th Annual Meeting of the Western Section of the American Urological Association being held in Monterey, California. The podium presentation will be given by Dr. Barrett Cowan of Denver. Dr. Cowan is an independent clinical investigator who has participated in the NX-1207 U.S. clinical trials for 4 years. The Nymox investigational drug has entered Phase 3 development.

In multicenter U.S. clinical trials to date NX- 1207 has been found to produce improvements in BPH symptom score that are approximately double that reported for currently approved BPH drugs without the side effects associated with those drugs, which can include sexual dysfunction, blood pressure changes and other adverse reactions. Patients notice improvement as early as a week or two after treatment. Follow-up studies have shown that many men showed continued benefit from a single NX-1207 treatment for 2 years or more.

NX-1207 involves a new targeted approach to the treatment of BPH. The drug is injected by a urologist in an office procedure directly into the zone of the prostate where the enlargement occurs. The injection takes only a few minutes and involves little or no pain or discomfort. Unlike currently approved BPH medications, NX-1207 treatment does not require the patient to take pills daily for the rest of his life.

BPH or enlarged prostate is one of the most commonly diagnosed diseases in the male U.S. population with a large portion of any primary care physician's or urologist's practice consisting of BPH management. The disorder affects approximately half of men over age 50 and close to 90% of men by age 80, and is associated with growth in prostate size as men age. BPH causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800- 936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities